Inify Laboratories AB — Director's Dealing 2026

Jan 27, 2026

Inify Laboratories - mandatory notification of trade

Inify Laboratories - mandatory notification of trade

Stockholm, Sweden, 27 January 2026; Inify Laboratories AB (publ.) (the

"Company") announces that the below primary insiders were allocated new shares

at the subscription price in the repair issue announced by the Company on 9

December 2025 (the "Repair Issue"), as further specified in the attached

notification forms:

-          Monsun AS, a company closely associated with board member Magne

Jordanger, has been allocated 898,204 Shares in the Repair Issue. Magne

Jordanger will, through the companies Monsun AS and Gallivant S.a.r.l. and

subject to completion of the Repair Issue and the Private Placement, own

76,868,249 shares in the Company.

-          Olof Sandén, chairman of the board, has been allocated 43,139 shares

in the Repair Issue. Sandén will, subject to the completion of the Repair Issue

own 159,979 shares in the Company.

-          Martin Ingvar, member of the board, has been allocated 67,132 shares

in the Repair Issue. Ingvar will, subject to the completion of the Repair Issue

own 283,195 shares in the Company.

-          Fredrik Palm, CEO of the Company, has been allocated 36,564 shares in

the Repair Issue. Palm will, subject to the completion of the Repair Issue own

139,613 shares in the Company.

-          Ann-Charlotte Linderoth, CFO of the Company, has been allocated

26,433 shares in the Repair Issue. Linderoth will, subject to the completion of

the Repair Issue own 99,433 shares in the Company.

For further information, please contact CEO, Fredrik Palm,

fredrik.palm@inify.com, or visit https://www.inify.com.

This information is subject to the disclosure requirements in the EU Market

Abuse Regulation (EU 596/2014 article 19) and section 5-12 of the Norwegian

Securities Trading Act.

The future of diagnostics

Inify Laboratories offers diagnostics through specialised laboratory services in

histopathology, with a focus on streamlining patient pathways. The company

performs clinical diagnostics in prostate cancer and gastroenterology, providing

an integrated service that spans from early sample handling to final diagnosis.

The laboratory system is scalable both in handling large volumes of patient

samples and for replicating in new locations.

Quality and response times are optimised in every step - from logistics to

tissue preparation and diagnosis - using a fully digital, standardised and AI

-assisted workflow. The diagnosis is always performed by a pathologist and is

assisted by Inify's proprietary AI, proven to have world-leading precision in

clinical evaluations. The entire workflow is supported by a tailor-made system

that also enables development to include additional diagnostic areas.

Inify Laboratories is an international group headquartered in Stockholm, Sweden,

with local laboratories in Sweden and the UK. The company's share is listed on

Euronext Growth Oslo (https://live.euronext.com/en/product/equities/SE0017486103

-MERK) under the ticker

INIFY. (https://live.euronext.com/en/product/equities/SE0017486103-MERK)